Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review

19 Scopus Citations
View graph of relations

Author(s)

  • Yushuai Liu
  • Yuanyuan Geng
  • Beilei Yue
  • Jing Huang
  • Honglin Jin

Related Research Unit(s)

Detail(s)

Original languageEnglish
Article number832942
Journal / PublicationFrontiers in Immunology
Volume12
Online published17 Jan 2022
Publication statusPublished - Jan 2022

Link(s)

Abstract

Cancer immunotherapy can boost the immune response of patients to eliminate tumor cells and suppress tumor metastasis and recurrence. However, immunotherapy resistance and the occurrence of severe immune-related adverse effects are clinical challenges that remain to be addressed. The tumor microenvironment plays a crucial role in the therapeutic efficacy of cancer immunotherapy. Injectable hydrogels have emerged as powerful drug delivery platforms offering good biocompatibility and biodegradability, minimal invasion, convenient synthesis, versatility, high drug-loading capacity, controlled drug release, and low toxicity. In this review, we summarize the application of injectable hydrogels as a unique platform for targeting the immunosuppressive tumor microenvironment.

Research Area(s)

  • abscopal effect, cancer immunotherapy, controlled drug release, immunogenic cell death, injectable hydrogels, tumor microenvironment (TME)

Citation Format(s)

Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment. / Liu, Yushuai; Geng, Yuanyuan; Yue, Beilei et al.
In: Frontiers in Immunology, Vol. 12, 832942, 01.2022.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review

Download Statistics

No data available